Zealand Pharma — Maj 2022
-
Fornemt tak
-
Pæn interesse inden regnskab i næste uge - any news?
-
Kun i småtingsafdelingen. Kan se at Intomics hvis platform Zealand Pharma benytter er blevet solgt.
"Lyngby-virksomheden Intomics solgt til amerikansk selskab"
Lyngby-virksomheden Intomics solgt til amerikansk selskab
Intomics, der arbejder med bioinformatik samt foretager dataanalyse til medicinal- og biotekindustrien, er blevet opkøbt af det amerikanske konsulent- og servicefirma ZS.
(medwatch.dk)
-
"Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development process"
(June 10, 2020)
-
tak @exitnu
-
Zealand Pharma ændrer finansieringsaftale med Oberland Capital https://proinvestor.com/investornyt/821762/zealand-pharma-aendrer-finansieringsaftale-med-oberland-capital
-
Credit Suisse Group er gået under 5 % ejerskab
-
Q&A med Zealand Pharma med Adam Stensberg er d. 20. maj kl. 15. Stil gerne spørgsmål allerede nu.
-
fornemt, tak
-
Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development
• Revenue: DKK 15.1 million / USD 2.3 million (DKK 5.7 million / USD 0.9 million in the first three months of 2021).
• Net operating expenses: DKK -314.2 million / USD -46.9 million (DKK -266.7 million / USD -42.0 million in the first three months of 2021). -
• Net operating result: DKK -302.0 million / USD -45.1 million (DKK -261.1 million / USD -41.2 million in the first three months of 2021).
• Net financial items: DKK 133.0 million / USD 19.9 million (DKK 19.8 million / USD 3.1 million in the first three months of 2021). -
• Net result from Discontinued Operations Related to Restructuring: DKK -41.8 million / USD -6.2 million (DKK 0.0 million / USD 0.0 million in the first three months of 2021).
• Cash, cash equivalents, and marketable securities: DKK 1,123.2 million / USD 167.6 million as of March 31, 2022 (March 31, 2021: DKK 1,604.1 million / USD 252.9 million). -
Financial guidance for 2022
On March 30, 2022 Zealand updated the guidance for net product revenue from the sales of commercial products to be DKK 115 million +/- 10%. This was a decrease of 120 million Danish kroner from the guidance issued on March 10, 2022. Combined sales of V-Go and Zegalogue in Q1 were 39.2 million Danish kroner and in line with the updated guidance.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind